The aim of neoadjuvant treatment in non-small cell lung cancer (NSCLC) is to eliminate
micrometastatic disease to facilitate surgical resection. Neoadjuvant chemotherapy (ChT) in …

Stage III non-small cell lung cancer (NSCLC) is a very heterogeneous disease that
encompasses patients with resected, potentially resectable and unresectable tumours. To …

Background CMTM6 was identified as an important regulator of the PD-L1 protein. The role
of CMTM6 in lung adenocarcinoma (LUAD) has so far remained unclear. We aimed at …

Aim: The aim of this systematic literature review was to describe treatment patterns in
nonmetastatic non-small-cell lung cancer. Methods: A search was conducted in MEDLINE …

Background: The significance of long non-coding RNAs (lncRNAs) as pivotal mediators of
histone acetylation and their influential role in predicting the prognosis of lung …

Background A growing body of evidence has proven that long noncoding ribonucleic acids
(lncRNAs) are important epigenetic regulators that play crucial parts in the pathogenesis of …

Lung adenocarcinoma is still cancer with the highest mortality. Hypoxia and immunity play
an essential role in the occurrence and development of tumors. Therefore, this study is …

Aim To compare neoadjuvant high-dose chemoradiotherapy (CRT) to neoadjuvant
chemotherapy (CHT) in patients with resectable, stage IIIA-N2 non-small-cell lung cancer …

Lung cancer screening programs with computed tomography of the chest reduce mortality
by more than 20%. Yet, they have not been implemented widely because of logistic and cost …

Introduction The standard of care for stage IIIA (N2) non–small-cell lung cancer (NSCLC)
includes concurrent definitive chemoradiation (dCRT) followed by durvalumab, thus …